Ibogaine is a Schedule III controlled substance under Canada's Controlled Drugs and Substances Act (CDSA), making its possession, sale, and distribution illegal without federal authorization. Last verified: April 2026.

Current Legal Status

Ibogaine appears in Schedule III of the Controlled Drugs and Substances Act, S.C. 1996, c. 19. Schedule III substances are subject to criminal penalties for unauthorized possession, trafficking, production, and importation. Unlike Schedule I substances (which carry the most severe penalties), Schedule III offences are prosecuted by indictment or summary conviction, but the substance remains firmly controlled.

Key legal parameters under the CDSA include:

  • Possession: Unauthorized possession is a criminal offence under s. 4 of the CDSA.
  • Trafficking and production: Prohibited under ss. 5 and 7, with penalties up to 10 years imprisonment on indictment for Schedule III substances.
  • Importation/exportation: Prohibited under s. 6 without a valid permit or exemption.
  • Section 56 exemptions: Under s. 56 of the CDSA, the Minister of Health may grant a personal or class exemption for scientific, medical, industrial, or other purposes deemed in the public interest. Research institutions, licensed dealers, and clinical trial sponsors can apply through Health Canada's Office of Controlled Substances.

Religious or ceremonial use: Canada does not currently recognize a formal religious exemption for ibogaine equivalent to the protections granted for peyote in some U.S. contexts. Indigenous ceremonial use of ibogaine is not established in Canadian traditional practice (ibogaine originates from the Central African Tabernanthe iboga plant), so no carve-out exists on that basis.

Noribogaine (the primary metabolite of ibogaine): Noribogaine is not explicitly named in any Schedule of the CDSA. However, it is likely subject to control either as a metabolite considered under analog provisions, or through Health Canada's interpretation of the schedules. The legal status of noribogaine remains uncertain and has not been definitively adjudicated in Canadian courts. Individuals and researchers should seek qualified legal counsel before assuming noribogaine is uncontrolled.

Important: No licensed ibogaine treatment clinic currently operates legally in Canada for general patient use. Any facility offering ibogaine outside a Health Canada–authorized clinical trial or Section 56 exemption is operating outside the law.

Treatment Centers

Currently, there are no licensed ibogaine clinics operating openly for general patients within Canada. Some Canadians have historically traveled to clinics in Mexico, Costa Rica, or other jurisdictions where ibogaine is unscheduled or operates in a legal gray zone.

Within Canada, ibogaine may only be administered legally as part of a Health Canada–approved clinical trial (under the Food and Drug Regulations, Division 5) or through a formal Section 56 exemption granted by the Minister of Health. As clinical research activity around ibogaine has grown, a small number of university-affiliated and private research groups have pursued or received authorization for studies, particularly focused on opioid use disorder and post-traumatic stress.

For a current directory of authorized research sites and any emerging licensed facilities, see our full clinic directory, which is updated as new authorizations are announced.

How People Access Ibogaine in Canada

The following reflects documented patterns of access. This is factual reporting, not a recommendation or endorsement of any method.

  • Clinical trial enrollment: The most legally straightforward path within Canada. Participants in approved trials receive ibogaine under medical supervision with full Health Canada oversight. Eligibility criteria are typically strict, and trials are not always recruiting.
  • Section 56 exemption (individual): A person may apply to Health Canada for an individual s. 56 exemption on medical or scientific grounds. These are rarely granted for individual patients outside a research framework and require substantial documentation.
  • International travel: Many Canadians travel to Mexico (where ibogaine clinics operate in a legal gray zone), Costa Rica, the Netherlands, or other countries. This is the most common practical route for those seeking treatment outside a trial. Travelers bear all medical risks associated with less-regulated environments.
  • Underground or informal access: Ibogaine is sourced and administered outside any legal framework by some individuals. This carries serious legal risk (CDSA criminal liability) and significant medical risk in the absence of clinical oversight.

Recent Legal Developments

Canada's regulatory posture on psychedelic-assisted therapies has shifted meaningfully in recent years, though ibogaine-specific reform lags behind psilocybin and MDMA:

  • Health Canada Special Access Program (SAP) expansion (2022): Amendments to the Food and Drug Regulations that came into force in 2022 expanded the SAP to allow authorized practitioners to request restricted drugs — including CDSA Schedule I–IV substances — for patients with serious or life-threatening conditions where conventional treatments have failed. Ibogaine is theoretically eligible for SAP requests, though approvals remain rare and require compelling clinical justification.
  • Growing clinical trial activity: Several Canadian research institutions have pursued or received authorization for ibogaine studies focused on opioid use disorder, particularly given Canada's ongoing toxic drug supply crisis. Studies at institutions in British Columbia and Ontario have advanced the evidence base and kept ibogaine in active regulatory conversation.
  • Parliamentary and public health attention: The opioid overdose crisis has prompted broader parliamentary discussion of novel treatments, with ibogaine mentioned in committee testimony and advocacy submissions. No legislation to reschedule or create a regulated treatment framework has been tabled as of April 2026, but advocacy from harm-reduction and addiction medicine communities continues.
  • British Columbia decriminalization context: B.C.'s pilot personal-possession decriminalization (for certain substances, January 2023–May 2024) did not include Schedule III substances such as ibogaine and was subsequently reversed by the provincial government in any event. This development does not affect ibogaine's federal scheduling.

Risks of Seeking Treatment in Canada

Regardless of how ibogaine is accessed, the following risks apply and are heightened outside of rigorously monitored clinical settings:

  • Cardiac risk: Ibogaine prolongs the QT interval and has been associated with fatal arrhythmias, including torsades de pointes. Pre-treatment cardiac screening (12-lead ECG, electrolyte panel) and continuous cardiac monitoring during administration are considered minimum safety standards. Underground settings typically cannot provide this.
  • No quality control outside clinical trials: Ibogaine obtained outside Health Canada–authorized channels has no guaranteed purity, potency, or identity verification. Adulterants or misdosed material increase both toxicity and inefficacy risk.
  • No regulatory recourse: Adverse events occurring outside authorized settings cannot be reported to Health Canada's MedEffect system in the same way as trial adverse events. Victims of harm have limited legal recourse against informal providers.
  • Criminal liability: Possessing, transporting, or facilitating access to ibogaine outside a valid exemption or trial is a criminal offence under the CDSA. This applies to facilitators and patients alike.
  • Drug interactions: Ibogaine has dangerous interactions with opioids, certain antidepressants (particularly those affecting serotonin or QT interval), stimulants, and other substances. Medical history review and washout periods require qualified clinical oversight.

Frequently Asked Questions

No. Ibogaine is a Schedule III controlled substance under Canada's Controlled Drugs and Substances Act. Possession, trafficking, production, and importation without federal authorization are criminal offences. Authorized exceptions exist only for licensed researchers, clinical trial sponsors, and those holding a valid Section 56 exemption from the Minister of Health.
Section 56 of the CDSA authorizes the Minister of Health to exempt a person or class of persons from any provision of the Act for scientific, medical, industrial, or other public-interest purposes. Applications are submitted to Health Canada's Office of Controlled Substances. Individual patient exemptions are possible in principle but are rarely granted outside a clinical or research framework. Applicants typically need strong medical documentation and a supervising healthcare provider willing to take on regulatory responsibility. The process can take months.
Potentially, yes — but it is rare. Since 2022, Health Canada's Special Access Program has been expanded to cover restricted drugs including CDSA-scheduled substances for patients with serious or life-threatening conditions where conventional treatments are inadequate. A licensed Canadian physician must submit the SAP request on the patient's behalf, and Health Canada reviews each case individually. Approvals are not guaranteed, and practitioners must be prepared to manage the clinical complexities of ibogaine administration.
Yes, a small number of ibogaine clinical trials have received Health Canada authorization, primarily focused on opioid use disorder. Enrollment is limited and governed by strict eligibility criteria (including cardiac health, psychiatric history, and current medication use). The best way to find active Canadian trials is to search Health Canada's Clinical Trials Database and ClinicalTrials.gov using the search term "ibogaine." Our clinic directory also notes research sites when publicly announced.
Traveling abroad to receive ibogaine treatment is not in itself a criminal offence under Canadian law — you are not importing a substance simply by receiving treatment overseas. However, bringing ibogaine back into Canada after treatment would constitute importation of a Schedule III substance and is a CDSA offence. Additionally, Canadians bear all the medical and safety risks associated with treatment in less-regulated foreign jurisdictions. Traveling to a country where ibogaine is legal or operates in a regulatory gray zone (such as Mexico or Costa Rica) is the most common route taken by Canadians seeking treatment, but it carries no government oversight or protection.
Noribogaine, the primary active metabolite of ibogaine, is not explicitly listed in any Schedule of the CDSA. Its legal status in Canada is genuinely uncertain. It may be considered subject to control through analog provisions or through Health Canada's interpretation of the ibogaine entry, but this has not been definitively resolved by the courts or by formal regulatory guidance. Anyone working with noribogaine in a research or clinical context should obtain a specific legal opinion before proceeding. Assuming it is freely legal because it is unlisted would be legally risky.
Ibogaine has appeared in parliamentary committee testimony and in submissions by harm-reduction and addiction medicine advocates, particularly in the context of Canada's opioid overdose crisis. However, as of April 2026, no legislation has been introduced to reschedule ibogaine, create a regulated treatment framework, or establish an ibogaine-specific exemption pathway. Reform momentum is present in the research and advocacy communities, but formal legislative change has not materialized. The trajectory of psychedelic policy reform in Canada (led primarily by psilocybin developments) may eventually extend to ibogaine, but the timeline is uncertain.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.